VanEck Biotech ETF (NASDAQ:BBH) Short Interest Update

VanEck Biotech ETF (NASDAQ:BBH) saw a large decline in short interest during the month of June. As of June 30th, there was short interest totaling 4,064 shares, a decline of 45.1% from the June 15th total of 7,403 shares. Approximately 0.2% of the company’s shares are sold short. Based on an average trading volume of 6,008 shares, the short-interest ratio is presently 0.7 days.

Insider Buying and Selling at VanEck Biotech ETF

In other news, major shareholder Sardar Biglari sold 6,533 shares of the stock in a transaction on Wednesday, July 15th. The stock was sold at an average price of $16.71, for a total value of $109,166.43. Following the transaction, the insider owned 3,552,710 shares of the company’s stock, valued at $59,365,784.10. This represents a 0.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders sold 10,493 shares of company stock valued at $175,335.

Hedge Funds Weigh In On VanEck Biotech ETF

Several institutional investors have recently modified their holdings of BBH. Ascent Advisors LLC bought a new position in VanEck Biotech ETF during the 1st quarter worth approximately $11,178,000. Northwestern Mutual Wealth Management Co. increased its stake in VanEck Biotech ETF by 40,463.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 494,061 shares of the company’s stock valued at $93,506,000 after purchasing an additional 492,843 shares in the last quarter. Conservest Capital Advisors Inc. raised its holdings in VanEck Biotech ETF by 22.9% in the first quarter. Conservest Capital Advisors Inc. now owns 20,276 shares of the company’s stock worth $3,812,000 after purchasing an additional 3,782 shares during the period. Atlas Capital Advisors Inc. acquired a new stake in VanEck Biotech ETF in the fourth quarter worth $1,079,000. Finally, Corient Private Wealth LLC raised its holdings in VanEck Biotech ETF by 9.6% in the fourth quarter. Corient Private Wealth LLC now owns 5,483 shares of the company’s stock worth $1,041,000 after purchasing an additional 478 shares during the period. 32.05% of the stock is currently owned by institutional investors and hedge funds.

VanEck Biotech ETF Stock Up 0.4%

Shares of VanEck Biotech ETF stock traded up $0.84 during trading on Friday, reaching $207.09. 498 shares of the company were exchanged, compared to its average volume of 5,966. The business has a 50-day moving average price of $192.67 and a 200-day moving average price of $191.86. VanEck Biotech ETF has a twelve month low of $154.75 and a twelve month high of $212.54.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.